A 42-year-old woman from rural Maharashtra presents with a 6-month history of polyuria, polydipsia, and progressive fatigue. She reports no prior diabetes diagnosis. On examination, she is lean (BMI 19 kg/m²), with no acanthosis nigricans or signs of insulin resistance. Fasting blood glucose is 156 mg/dL, and HbA1c is 9.2%. C-peptide level is 0.8 ng/mL (normal 1.1–4.4 ng/mL). Anti-GAD65 and anti-IA2 antibodies are positive. What is the most likely pathological mechanism underlying her diabetes?

Explanation

## Diagnosis: Latent Autoimmune Diabetes in Adults (LADA) ### Clinical Presentation This patient presents with features consistent with LADA (Type 1 diabetes in adults): - **Lean body habitus** (BMI 19) — argues against Type 2 diabetes - **Absence of insulin resistance markers** — no acanthosis nigricans, normal BMI - **Positive autoantibodies** (anti-GAD65, anti-IA2) — hallmark of autoimmune diabetes - **Low C-peptide** (0.8 ng/mL) — indicates reduced beta cell function - **Elevated fasting glucose and HbA1c** — reflects poor glycemic control ### Pathological Mechanism **Key Point:** LADA is characterized by slow, progressive autoimmune destruction of pancreatic beta cells, mediated by CD8+ T cells and B cells producing islet-specific autoantibodies (anti-GAD65, anti-IA2, anti-ZnT8). The pathophysiology unfolds in stages: 1. **Genetic predisposition** — HLA-DR3/DR4 heterozygotes at highest risk 2. **Environmental trigger** — viral infection, molecular mimicry, or dietary antigen exposure 3. **Autoimmune infiltration** — insulitis (CD8+ T cell and macrophage infiltration of islets) 4. **Beta cell apoptosis** — gradual loss of insulin-secreting capacity 5. **Absolute insulin deficiency** — eventual requirement for insulin therapy **High-Yield:** The positive autoantibodies (anti-GAD65, anti-IA2) confirm autoimmune beta cell destruction; low C-peptide confirms reduced secretory capacity. This is NOT insulin resistance. ### Differential Pathology | Mechanism | Type 1 / LADA | Type 2 | MODY | Mitochondrial | |---|---|---|---|---| | **Primary defect** | Autoimmune beta cell destruction | Insulin resistance + beta cell dysfunction | Monogenic (MODY 1–14) | mtDNA mutation | | **Autoantibodies** | Present (GAD, IA2, ZnT8) | Absent | Absent | Absent | | **C-peptide** | Low/absent | High (early) → low (late) | Variable | Low | | **BMI** | Lean | Obese/overweight | Lean or normal | Variable | | **Age of onset** | Childhood or adult (LADA) | Adult | Childhood/young adult | Variable | **Clinical Pearl:** LADA is sometimes called "Type 1.5 diabetes" because it bridges the slow autoimmune destruction of Type 1 with the adult presentation of Type 2. Antibody positivity is the diagnostic lynchpin. ### Why Option 0 Is Correct Autoimmune destruction of beta cells (confirmed by positive anti-GAD65 and anti-IA2 antibodies) leading to absolute insulin deficiency (evidenced by low C-peptide) is the core pathological mechanism in LADA. This patient will eventually require insulin therapy. [cite:Robbins 10e Ch 24]